Welcome to the UPF Digital Repository

A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: the role of platelet IRAS/Nischarin (I1-Imidazoline Receptor)

Show simple item record

dc.contributor.author Keller, Benjamin
dc.contributor.author Mestre-Pintó, Juan Ignacio
dc.contributor.author Álvaro-Bartolomé, María
dc.contributor.author Martínez-Sanvisens, Diana
dc.contributor.author Farré Albaladejo, Magí
dc.contributor.author García-Fuster, M. Julia
dc.contributor.author García Sevilla, Jesús
dc.contributor.author Torrens, Marta
dc.contributor.author The NEURODEP Group
dc.date.accessioned 2018-11-14T08:29:40Z
dc.date.available 2018-11-14T08:29:40Z
dc.date.issued 2017
dc.identifier.citation Keller B, Mestre-Pinto JI, Álvaro-Bartolomé M, Martinez-Sanvisens D, Farre M, García-Fuster MJ. Et al. A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: the role of platelet IRAS/Nischarin (I1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 1;8:258. DOI: 10.3389/fpsyt.2017.00258
dc.identifier.issn 1664-0640
dc.identifier.uri http://hdl.handle.net/10230/35746
dc.description.abstract The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD- comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.
dc.description.sponsorship The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economía y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Temáticas de Investigación Cooperativa en Salud–Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a “Ramón y Cajal” Researcher (MINECO-UIB). JG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Pérez, Soraya Martín, and Clara Gibert for their valuable assistance throughout the clinical part of the study.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartof Frontiers in Psychiatry. 2017 Dec 1;8:258
dc.rights copyright © 2017 Keller, Mestre-Pinto, Álvaro-Bartolomé, Martinez-Sanvisens, Farre, García-Fuster, García-Sevilla and Torrens. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject.other Antidepressius
dc.subject.other Cocaïna -- Efectes fisiològics
dc.subject.other Marcadors bioquímics
dc.title A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: the role of platelet IRAS/Nischarin (I1-Imidazoline Receptor)
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fpsyt.2017.00258
dc.subject.keyword IRAS/nischarin
dc.subject.keyword Acute tryptophan depletion
dc.subject.keyword Antidepressant drugs
dc.subject.keyword Cocaine use disorder
dc.subject.keyword Cocaine-induced depression
dc.subject.keyword Major depressive disorder
dc.subject.keyword Platelet biomarker
dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/SAF2011-29918
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2014-55903-R
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking